Different products are not interchangeable
Nicotinamide, nicotinamide riboside and NMN are different compounds. Findings for one product, dose and population cannot automatically be transferred to another product or intravenous treatment.
A randomised study of nicotinamide riboside in middle-aged and older adults investigated outcomes including NAD metabolism. Such findings do not establish treatment for ME/CFS or long COVID, or an extension of lifespan.
Methylation and homocysteine
Some pathways that break down nicotinamide use methyl groups. This raises a biological question for research, but does not prove that all NAD precursors raise homocysteine or that everyone needs additional methyl donors.
Homocysteine is influenced by several factors, including folate, vitamin B12 and kidney function. An abnormal result needs interpretation in context. Lowering a laboratory value does not automatically mean reducing disease risk.
What should an assessment clarify?
Which problem is being addressed, what evidence supports that specific product and which risks matter? A medicines and supplements list is often a more useful starting point than immediately ordering more tests.
Neither a genetic variant nor an NAD measurement independently provides a treatment protocol. Avoid dosing advice that ignores other treatment or uncertainty in long-term evidence.
Sources and further reading
- Martens et al. — Chronic nicotinamide riboside supplementation in healthy middle-aged and older adults (2018)
- NHS — Vitamin B12 or folate deficiency anaemia
- NHS — B vitamins and folic acid
- NCCIH — Using Dietary Supplements Wisely
This is general information and does not replace an individual medical assessment.
